Literature DB >> 26135725

[Advanced and Metastatic Lung Cancer – What is new in the Diagnosis and Therapy?].

Sacha I Rothschild1.   

Abstract

Lung cancer is one of the most common types of malignancies worldwide. The majority of patients are diagnosed with an incurable advanced/metastatic stage disease. Palliative treatment approaches improve the survival and the quality of life of these patients. Lung cancer is subdivided according to histology and molecular biology. The most important classification separates small cell from non-small cell lung cancer. In the subgroup of non-small cell lung cancer novel treatment approaches coming along with an improved prognosis have been established during the last decade. The current manuscript provides an overview on current treatment options for metastatic lung cancer. Furthermore, an outlook on promising future treatment options is provided.

Entities:  

Keywords:  Bronchialkarzinom; Chemotherapie; cancer du poumon; cancer du poumon non à petites cellules; cancer du poumon à petites cellules; chemotherapy; chimiothérapie; kleinzelliges Bronchialkarzinom; lung cancer; nicht-kleinzelliges Bronchialkarzinom; non-small cell lung cancer; small cell lung cancer; targeted therapy; traitement personnalisé; zielgerichtete Therapie

Mesh:

Year:  2015        PMID: 26135725     DOI: 10.1024/1661-8157/a002058

Source DB:  PubMed          Journal:  Praxis (Bern 1994)        ISSN: 1661-8157


  7 in total

1.  Long non-coding RNA H19 and the underlying epigenetic function in response to DNA damage of lung cancer cells.

Authors:  Dongjie Wang; Yajiao Sun; Lin Lin; Yulan Sang; Fan Yang; Jiawen Zhang; Li Jia; Ziping Xu; Wei Zhang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Long non-coding RNA DGCR5 is involved in the regulation of proliferation, migration and invasion of lung cancer by targeting miR-1180.

Authors:  En-Guo Chen; Ji-Song Zhang; Shan Xu; Xiao-Jing Zhu; Hui-Hui Hu
Journal:  Am J Cancer Res       Date:  2017-07-01       Impact factor: 6.166

3.  ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response.

Authors:  Hongchang Shen; Liguang Wang; Jiangang Zhang; Wei Dong; Tiehong Zhang; Yang Ni; Hongxin Cao; Kai Wang; Yun Li; Yibing Wang; Jiajun Du
Journal:  Oncol Rep       Date:  2016-12-28       Impact factor: 3.906

4.  SPP1 and AGER as potential prognostic biomarkers for lung adenocarcinoma.

Authors:  Weiguo Zhang; Junli Fan; Qiang Chen; Caipeng Lei; Bin Qiao; Qin Liu
Journal:  Oncol Lett       Date:  2018-03-12       Impact factor: 2.967

5.  Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis.

Authors:  Qiong Wu; Bo Zhang; Yidan Sun; Ran Xu; Xinyi Hu; Shiqi Ren; Qianqian Ma; Chen Chen; Jian Shu; Fuwei Qi; Ting He; Wei Wang; Ziheng Wang
Journal:  Onco Targets Ther       Date:  2019-05-13       Impact factor: 4.147

6.  S-nitrosylation of the Peroxiredoxin-2 promotes S-nitrosoglutathione-mediated lung cancer cells apoptosis via AMPK-SIRT1 pathway.

Authors:  Yihan Zhang; Changning Sun; Guokai Xiao; Hui Shan; Luyao Tang; Yujiao Yi; Wengong Yu; Yuchao Gu
Journal:  Cell Death Dis       Date:  2019-04-15       Impact factor: 8.469

7.  Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway.

Authors:  Chengtao Yu; Fang Tian; Jun Liu; Minhui Su; Min Wu; Xuejun Zhu; Wang Qian
Journal:  Cell Prolif       Date:  2019-04-22       Impact factor: 6.831

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.